Histopathological regression after taxane based neoadjuvant chemotherapy in patients with resectable gastric or gastro-oesophageal junction adenocarcinoma.
作者信息
Mitra Abhishek, Shrikhande Shailesh V, Sirohi Bhawna
机构信息
GI and HPB Service, Department of Surgical Oncology, Tata Memorial Hospital, Parel, Mumbai, India.
Department of Medical Oncology, Barts Health NHS Trust, London, UK.
出版信息
Transl Gastroenterol Hepatol. 2017 May 16;2:46. doi: 10.21037/tgh.2017.05.01. eCollection 2017.
Abstract
摘要
相似文献
1
Histopathological regression after taxane based neoadjuvant chemotherapy in patients with resectable gastric or gastro-oesophageal junction adenocarcinoma.
Transl Gastroenterol Hepatol. 2017 May 16;2:46. doi: 10.21037/tgh.2017.05.01. eCollection 2017.
2
Histopathological regression after neoadjuvant docetaxel, oxaliplatin, fluorouracil, and leucovorin versus epirubicin, cisplatin, and fluorouracil or capecitabine in patients with resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4-AIO): results from the phase 2 part of a multicentre, open-label, randomised phase 2/3 trial.
Lancet Oncol. 2016 Dec;17(12):1697-1708. doi: 10.1016/S1470-2045(16)30531-9. Epub 2016 Oct 22.
3
Tumour regression grade (TRG) analyses in patients with resectable gastro-oesophageal adenocarcinomas treated with platinum-based neoadjuvant chemotherapy.
Histopathology. 2009 Oct;55(4):399-406. doi: 10.1111/j.1365-2559.2009.03404.x.
4
Exclusive neoadjuvant chemotherapy in locally advanced resectable gastric and gastro-esophageal junction adenocarcinoma.
Dig Liver Dis. 2017 May;49(5):552-556. doi: 10.1016/j.dld.2016.12.025. Epub 2017 Jan 16.
5
Outcome of neoadjuvant therapies for cancer of the oesophagus or gastro-oesophageal junction based on a national data registry.
Br J Surg. 2016 Dec;103(13):1864-1873. doi: 10.1002/bjs.10304. Epub 2016 Sep 30.
6
Trastuzumab emtansine versus taxane use for previously treated HER2-positive locally advanced or metastatic gastric or gastro-oesophageal junction adenocarcinoma (GATSBY): an international randomised, open-label, adaptive, phase 2/3 study.
Lancet Oncol. 2017 May;18(5):640-653. doi: 10.1016/S1470-2045(17)30111-0. Epub 2017 Mar 23.
7
Preoperative ECF chemotherapy in gastro-oesophageal adenocarcinoma.
Clin Oncol (R Coll Radiol). 2000;12(3):182-7. doi: 10.1053/clon.2000.9147.
8
Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a randomised, phase 2/3 trial.
Lancet. 2019 May 11;393(10184):1948-1957. doi: 10.1016/S0140-6736(18)32557-1. Epub 2019 Apr 11.
9
Survival benefit and additional value of preoperative chemoradiotherapy in resectable gastric and gastro-oesophageal junction cancer: a direct and adjusted indirect comparison meta-analysis.
Eur J Surg Oncol. 2015 Mar;41(3):282-94. doi: 10.1016/j.ejso.2014.11.039. Epub 2014 Nov 27.
10
Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial.
Lancet. 2017 Dec 2;390(10111):2461-2471. doi: 10.1016/S0140-6736(17)31827-5. Epub 2017 Oct 6.
本文引用的文献
1
Comparison of five tumor regression grading systems for gastric adenocarcinoma after neoadjuvant chemotherapy: a retrospective study of 192 cases from National Cancer Center in China.
BMC Gastroenterol. 2017 Mar 14;17(1):41. doi: 10.1186/s12876-017-0598-5.
2
Peri-operative chemotherapy with or without bevacizumab in operable oesophagogastric adenocarcinoma (UK Medical Research Council ST03): primary analysis results of a multicentre, open-label, randomised phase 2-3 trial.
Lancet Oncol. 2017 Mar;18(3):357-370. doi: 10.1016/S1470-2045(17)30043-8. Epub 2017 Feb 3.
3
Histopathological regression after neoadjuvant docetaxel, oxaliplatin, fluorouracil, and leucovorin versus epirubicin, cisplatin, and fluorouracil or capecitabine in patients with resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4-AIO): results from the phase 2 part of a multicentre, open-label, randomised phase 2/3 trial.
Lancet Oncol. 2016 Dec;17(12):1697-1708. doi: 10.1016/S1470-2045(16)30531-9. Epub 2016 Oct 22.
4
Preoperative versus postoperative docetaxel-cisplatin-fluorouracil (TCF) chemotherapy in locally advanced resectable gastric carcinoma: 10-year follow-up of the SAKK 43/99 phase III trial.
Ann Oncol. 2016 Apr;27(4):668-73. doi: 10.1093/annonc/mdv620. Epub 2015 Dec 27.
5
Influence of Different Neoadjuvant Chemotherapy Regimens on Response, Prognosis, and Complication Rate in Patients with Esophagogastric Adenocarcinoma.
Ann Surg Oncol. 2015 Dec;22 Suppl 3:S905-14. doi: 10.1245/s10434-015-4617-x. Epub 2015 May 22.
6
Epirubicin, oxaliplatin, and capectabine is just as "MAGIC"al as epirubicin, cisplatin, and fluorouracil perioperative chemotherapy for resectable locally advanced gastro-oesophageal cancer.
J Cancer Res Ther. 2014 Oct-Dec;10(4):866-70. doi: 10.4103/0973-1482.146122.
7
NeoFLOT: Multicenter phase II study of perioperative chemotherapy in resectable adenocarcinoma of the gastroesophageal junction or gastric adenocarcinoma-Very good response predominantly in patients with intestinal type tumors.
Int J Cancer. 2015 Aug 1;137(3):678-85. doi: 10.1002/ijc.29403. Epub 2015 Feb 25.
8
Treatment of patients with advanced gastric cancer: experience from an Indian tertiary cancer center.
Med Oncol. 2014 Oct;31(10):138. doi: 10.1007/s12032-014-0138-x. Epub 2014 Sep 17.
9
Survival and recurrence patterns after neoadjuvant docetaxel, cisplatin, and 5-fluorouracil (DCF) for locally advanced esophagogastric adenocarcinoma.
Ann Surg Oncol. 2015 Jan;22(1):324-30. doi: 10.1245/s10434-014-3875-3. Epub 2014 Jul 15.
10
The feasibility of triple-drug chemotherapy combination in older adult patients with oesophagogastric cancer: a randomised trial of the Arbeitsgemeinschaft Internistische Onkologie (FLOT65+).
Eur J Cancer. 2013 Mar;49(4):835-42. doi: 10.1016/j.ejca.2012.09.025. Epub 2012 Oct 11.
Zotero 插件